Table 4.

Multivariate odds ratios for the risk of MI in the nested case–control analysis

	All matched case–control pairs				Subset of cases and controls without CHD
	I		II		I		II
	OR	(95 % CI)	OR	(95 % CI)	OR	(95 % CI)	OR	(95 % CI)
Log CRP, prior MIa	1.58	(1.07; 2.33)			1.60	(1.04; 2.46)
Log CRP, total observationa			1.47	(1.00; 2.16)			1.44	(0.94; 2.19)
csDMARDs only	Ref.		Ref.		Ref.		Ref.
TNFi	0.96	(0.41; 2.22)	0.91	(0.40; 2.10)	1.24	(0.49; 3.16)	1.22	(0.49; 3.05)
Other bDMARDs	1.13	(0.34; 3.71)	0.85	(0.27; 2.72)	0.86	(0.19; 3.84)	0.53	(0.13; 2.18)
Glucocorticoids <5 mg/day	Ref.		Ref.		Ref.		Ref.
5–10 mg/day	1.33	(0.61; 2.89)	1.22	(0.56; 2.68)	1.42	(0.59; 3.43)	1.32	(0.55; 3.17)
≥10 mg/day	2.17	(0.69; 6.81)	1.83	(0.57; 5.85)	2.48	(0.72; 8.59)	2.18	(0.61; 7.79)
No CV treatmentb	2.76	(0.91; 8.32)	2.66	(0.88; 8.00)	2.42	(0.55; 10.77)	2.66	(0.60; 11.72)
Smoking never	Ref.		Ref.		Ref.		Ref.
Smoking ever	3.33	(1.45; 7.63)	2.93	(1.29; 6.66)	2.13	(0.85; 5.32)	2.03	(0.69; 5.93)
Smoking status unknown	2.15	(0.82; 5.66)	2.12	(0.80; 5.65)	1.74	(0.62; 4.88)	1.84	(0.65; 5.21)
Diabetes	2.08	(0.84; 5.18)	2.32	(0.94; 5.71)	1.95	(0.68; 5.63)	1.92	(0.67; 5.51)

Case–control pairs with missing C-reactive protein (CRP) values were not considered in this analysis. ^aAll CRP values were log-transformed. Analysis I: CRP values of the last 6 months prior to the myocardial infarction (MI)/index date, Analysis II: averaged CRP values from baseline until the MI/index date. ^bNo CV treatment: one or more of the types of reported cardiovascular disease (CVD) at baseline (hypertension, coronary heart disease, heart failure and hyperlipoproteinaemia) is not reported as being treated. Baseline information was used for no CV treatment, smoking and diabetes. All other treatments are values within 6 months before the MI/index date

OR odds ratio, CI confidence interval, CHD coronary heart disease, bDMARD biologic disease-modifying anti-rheumatic drug, csDMARD conventional synthetic DMARD, TNFi tumour necrosis factor inhibitor